Latest News About Charm

I can help with the latest news about Charm. Here’s a quick update based on recent public reporting:

• CHARM Therapeutics, a London-based AI-powered biotech company focused on menin inhibitors for AML, announced key corporate moves in 2025, including a Series B financing of $80 million and executive appointments designed to accelerate its clinical program. This financing was led by NEA and SR One and accompanied by participation from existing investors, signaling strong investor confidence in their AI-driven approach to overcome resistance mutations in AML [CHARM Therapeutics press releases; GlobeNewswire summaries].
• In September 2025, CHARM Therapeutics named Dr. Erkut Bahceci as Chief Medical Officer, aligning leadership with its upcoming clinical development timeline and strategic goals for first-in-human studies in AML planned around 2026 [CHARM Therapeutics press release; GlobeNewswire item].
• The company’s 2025 updates also highlighted advancement of its CHM-029 program, described as a next-generation menin inhibitor designed to retain potency against known resistance mutations, with preclinical data indicating robust, dose-dependent tumor regression in AML models and readiness for clinical evaluation [GlobeNewswire press release, CHARM Therapeutics communications].

If you’d like, I can pull the latest publicly available press releases and summarize them in more detail, or focus on a specific topic (e.g., clinical timelines, funding rounds, leadership). I can also track future CHARM updates and provide concise briefings.

Would you prefer a focused timeline, a company-structure snapshot, or a comparison of CHARM’s program with peers in the AML space?